ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer

Wang, Fen*; Jin, Feng; Cheng, Boran; Zhang, Yue; Zhou, Qing; Wang, Shubin广东省人民医院; 北京大学; 南方医科大学
Journal of Cancer Research and Clinical Oncology2022-7DOI: 10.1007/s00432-021-03752-x
3被引6阅读
引用收藏
分享

摘要

Purpose Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer (aNSCLC) in the real world. Methods Patients with aNSCLC receiving anlotinib were enrolled in two cohorts (treatment naive and previously treated). The endpoints included progression-free survival (PFS), overall survival (OS) and anlotinib-related adverse events (ar-AEs). Results 203 patients accrued in the study. In the treatment-naive cohort (n = 80), the PFS was 7.4 (95% confidence interval [CI] 4.1-10.7) and OS was 10.8 (95% CI 5.8-15.8) months of monotherapy group (immature survival for combination group). In previously treated cohort (n = 123), the PFS was 8.0 months (95% CI 6.1-9.9) in the combination group and 4.3 months (95% CI 2.1-6.6) in the monotherapy group (hazard ratio [HR] 0.49; 95% CI 0.29-0.83; p = 0.007), respectively. The OS was 18.5 months (95% CI 10.5-26.6) in the combination group and 7.8 months (95% CI 7.1-8.4) in the monotherapy group (HR 0.38; 95% CI 0.22-0.66; p = 0.001), respectively. The ar-AEs of grade >= 3 in the monotherapy and the combination groups were hypertension (9.0 and 8.7%), fatigue (8.1 and 7.6%), hand-foot syndrome (8.1 and 6.5%), diarrhea (5.4 and 8.7%), proteinuria (5.4 and 5.4%), and mucositis oral (6.3 and 8.7%). Conclusion In aNSCLC, anlotinib monotherapy has a promising efficacy in the first-line setting. It may be an option for those who are ineligible for chemotherapy; anlotinib combination therapy in a >= second-line setting showed manageable toxicities and encouraging efficacy, indicating a good application prospect.

学科与关键词

关键词
AnlotinibNon-small cell lung cancerReal worldTyrosine kinase inhibitorAnti-angiogenesis
相关
加载中…
  • A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors
    Li, Shu-hui; Li, Yi-Wen; Li, Ying-Jue; Liu, Lin-Bo; Zhang, Qun; Lu, Dan*International Journal of General Medicine, 2023, 16: 4485-4498.
  • Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
    Shi, Jianhua; Cheng, Ying*; Wang, Qiming; Li, Kai; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, XiaolingFrontiers of Medicine, 2022, 16(5): 766-772.被引 5
  • Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutation
    Li, X.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Cancer Research and Clinical Oncology
发表日期
2022-07
卷期
第 148 卷, 第 7 期
页码
1721-1735
DOI
10.1007/s00432-021-03752-x
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Wu Jieping Medical Foundation [320.6750.19088-10]; Beijing Bethune Charitable Foundation [BQE-TY-SSPC(2)-S-01]; Shenzhen Sanming Project [SZSM201612041]

作者

  • W

    Wang, Fen (通讯) (第一作者)

    hong kong univ sci & technol · peking univ · 2 · guangdong prov peoples hosp · southern med univ

  • J

    Jin, Feng

    hong kong univ sci & technol · peking univ

查看全部 6 位作者收起作者
  • C

    Cheng, Boran

    hong kong univ sci & technol · peking univ

  • Z

    Zhang, Yue

    hong kong univ sci & technol · peking univ

  • Z

    Zhou, Qing

    2 · guangdong prov peoples hosp · southern med univ

  • W

    Wang, Shubin

    hong kong univ sci & technol · peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417